Erratum: Expression of Concern: Secretory Phosphatases Deficient Mutant of Mycobacterium tuberculosis Imparts Protection at the Primary Site of Infection in Guinea Pigs.(PLoS ONE (2013) 8: 10 (e77930) DOI: 10.1371/journal.pone.0077930);Secretory Phosphatases Deficient Mutant of Mycobacterium tuberculosis Imparts Protection at the Primary Site of Infection in Guinea Pigs

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Chauhan, Priyanka ^a   Reddy, P Vineel ^a   Singh, Ramandeep ^a,c   Jaisinghani, Neetika ^b   Gandotra, Sheetal ^b   Tyagi, Anil K ^a  

^a UNIVERSITY OF DELHI   (India)

^b CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^c Faridabad Gurugram Expressway   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; BCG VACCINE; MYCOBACTERIUM VACCINE; PROTEIN TYROSINE PHOSPHATASE; SECRETORY ACID PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL VIRULENCE; BACTERIUM MUTANT; COLONY FORMING UNIT; CONTROLLED STUDY; GENE DISRUPTION; GUINEA PIG; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INFECTION PREVENTION; INOCULATION; LIPID ANALYSIS; LIPID COMPOSITION; LUNG; MICROBIAL ATTENUATION; MPTPA GENE; MPTPB GENE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; SAPM GENE; SPLEEN; TUBERCULOSIS; VACCINATION;

ANIMALIA; BACILLI (CLASS); BACTERIA (MICROORGANISMS); CAVIA; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS;

ANIMALS; BLOTTING, SOUTHERN; COLONY COUNT, MICROBIAL; FEMALE; GUINEA PIGS; LUNG; MACROPHAGES; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PHOSPHORIC MONOESTER HYDROLASES; SPLEEN; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VIRULENCE;

EID: 84885696022     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0277782     Document Type: Erratum

References (51)

1. Walker KB, Brennan MJ, Ho MM, Eskola J, Thiry G, et al. (2010) The second Geneva Consensus: Recommendations for novel live TB vaccines. Vaccine 28: 2259-2270. doi:10.1016/j.vaccine.2009.12.083. PubMed: 20074686.
2. WHO (2012) Global tuberculosis report. Retrieved onpublished at whilst December year 1111 from http://wwwwhoint/tb/publications/global_report/gtbr12_mainpdf. Accessed 31st August 2013.
3. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375: 1830-1843. doi:10.1016/S0140-6736(10)60410-2. PubMed: 20488523.
4. Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, et al. (2009) Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136: 420-425. doi:10.1378/chest.08-2427. PubMed: 19349380.
5. McShane H, (2011) Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci 366: 2782-2789. doi:10.1098/rstb.2011.0097. PubMed: 21893541.
6. Brodin P, Majlessi L, Brosch R, Smith D, Bancroft G, et al. (2004) Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. J Infect Dis 190: 115-122. doi:10.1086/421468. PubMed: 15195250.
7. Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, et al. (2007) Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A 104: 5596-5601. doi:10.1073/pnas.0700869104. PubMed: 17372194.
8. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, et al. (1999) Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284: 1520-1523. doi:10.1126/science.284.5419.1520. PubMed: 10348738.
9. Hernàndez Pando R, Aguilar LD, Infante E, Cataldi A, Bigi F, et al. (2006) The use of mutant mycobacteria as new vaccines to prevent tuberculosis. Tuberculosis 86: 203-210. doi:10.1016/j.tube.2006.01.022. PubMed: 16542875.
10. Sambandamurthy VK, Jacobs WR Jr., (2005) Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect 7: 955-961. doi:10.1016/j.micinf.2005.04.001. PubMed: 15914065.
11. Hinchey J, Lee S, Jeon BY, Basaraba RJ, Venkataswamy MM, et al. (2007) Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 117: 2279-2288. doi:10.1172/JCI31947. PubMed: 17671656.
12. Martin C, Williams A, Hernandez-Pando R, Cardona PJ, Gormley E, et al. (2006) The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs. Vaccine 24: 3408-3419. doi:10.1016/j.vaccine.2006.03.017. PubMed: 16564606.
13. Ottenhoff TH, Kaufmann SH, (2012) Vaccines against tuberculosis: where are we and where do we need to go? PLOS Pathog 8: e1002607. PubMed: 22589713.
14. Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, et al. (2006) Mycobacterium tuberculosis ΔRD1 ΔpanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24: 6309-6320. doi:10.1016/j.vaccine.2006.05.097. PubMed: 16860907.
15. Waters WR, Palmer MV, Nonnecke BJ, Thacker TC, Scherer CF, et al. (2007) Failure of a Mycobacterium tuberculosis ΔRD1 ΔpanCD double deletion mutant in a neonatal calf aerosol M. bovis challenge model: comparisons to responses elicited by M. bovis bacille Calmette Guerin. Vaccine 25: 7832-7840. doi:10.1016/j.vaccine.2007.08.029. PubMed: 17931755.
16. Tuberculosis Vaccine candidates (2011). Retrieved onpublished at whilst December year 1111 from http://www.stoptb.org/wg/new_vaccines/assets/documents/TB%20Vaccine%20Pipeline_rAug%202012.pdf. Accessed 31st August 2013.
17. Beresford NJ, Mulhearn D, Szczepankiewicz B, Liu G, Johnson ME, et al. (2009) Inhibition of MptpB phosphatase from Mycobacterium tuberculosis impairs mycobacterial survival in macrophages. J Antimicrob Chemother 63: 928-936. doi:10.1093/jac/dkp031. PubMed: 19240079.
18. Saleh MT, Belisle JT, (2000) Secretion of an acid phosphatase (SapM) by Mycobacterium tuberculosis that is similar to eukaryotic acid phosphatases. J Bacteriol 182: 6850-6853. doi:10.1128/JB.182.23.6850-6853.2000. PubMed: 11073936.
19. Vergne I, Chua J, Lee HH, Lucas M, Belisle J, et al. (2005) Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 102: 4033-4038. doi:10.1073/pnas.0409716102. PubMed: 15753315.
20. Wong D, Chao JD, Av-Gay Y, (2013) Mycobacterium tuberculosis-secreted phosphatases: from pathogenesis to targets for TB drug development. Trends Microbiol 21: 100-109. doi:10.1016/j.tim.2012.09.002. PubMed: 23084287.
21. Festjens N, Bogaert P, Batni A, Houthuys E, Plets E, et al. (2011) Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis. EMBO. Mol Med 3: 222-234.
22. Saikolappan S, Estrella J, Sasindran SJ, Khan A, Armitige LY, et al. (2012) The fbpA/sapM double knock out strain of Mycobacterium tuberculosis is highly attenuated and immunogenic in macrophages. PLOS ONE 7: e36198. doi:10.1371/journal.pone.0036198. PubMed: 22574140.
23. Wong D, Bach H, Sun J, Hmama Z, Av-Gay Y, (2011) Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA) excludes host vacuolar-H+-ATPase to inhibit phagosome acidification. Proc Natl Acad Sci U S A 108: 19371-19376. doi:10.1073/pnas.1109201108. PubMed: 22087003.
24. Bach H, Papavinasasundaram KG, Wong D, Hmama Z, Av-Gay Y, (2008) Mycobacterium tuberculosis virulence is mediated by PtpA dephosphorylation of human vacuolar protein sorting 33B. Cell Host Microbe 3: 316-322. doi:10.1016/j.chom.2008.03.008. PubMed: 18474358.
25. Koul A, Choidas A, Treder M, Tyagi AK, Drlica K, et al. (2000) Cloning and characterization of secretory tyrosine phosphatases of Mycobacterium tuberculosis. J Bacteriol 182: 5425-5432. doi:10.1128/JB.182.19.5425-5432.2000. PubMed: 10986245.
26. Singh R, Rao V, Shakila H, Gupta R, Khera A, et al. (2003) Disruption of mptpB impairs the ability of Mycobacterium tuberculosis to survive in guinea pigs. Mol Microbiol 50: 751-762. doi:10.1046/j.1365-2958.2003.03712.x. PubMed: 14617138.
27. Zhou B, He Y, Zhang X, Xu J, Luo Y, et al. (2010) Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents. Proc Natl Acad Sci U S A 107: 4573-4578. PubMed: 20167798.
28. Hou S, Li X, Feng XZ, (2009) Method to improve DNA condensation efficiency by alkali treatment. Nucleosides Nucleotides Nucleic Acids 28: 725-735. doi:10.1080/15257770903155493. PubMed: 20183612.
29. Vilchèze C, Jacobs WR, (2007) Isolation and analysis of Mycobacterium tuberculosis mycolic acids. Curr Protoc Microbiol Pp. 10A.3: Unit 10A.3.1-10A.311. PubMed: 18770604.
30. Slayden RA, Barry CE 3rd, (2001) Analysis of the Lipids of Mycobacterium tuberculosis. Methods Mol Med 54: 229-245. PubMed: 21341079.
31. Reddy PV, Puri RV, Khera A, Tyagi AK, (2012) Iron storage proteins are essential for the survival and pathogenesis of Mycobacterium tuberculosis in THP-1 macrophages and the guinea pig model of infection. J Bacteriol 194: 567-575. doi:10.1128/JB.05553-11. PubMed: 22101841.
32. Jain R, Dey B, Dhar N, Rao V, Singh R, et al. (2008) Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung. PLOS ONE 3: e3869. doi:10.1371/journal.pone.0003869. PubMed: 19052643.
33. Kai M, Fujita Y, Maeda Y, Nakata N, Izumi S, et al. (2007) Identification of trehalose dimycolate (cord factor) in Mycobacterium leprae. FEBS Lett 581: 3345-3350. PubMed: 17601578.
34. Giovannini D, Cappelli G, Jiang L, Castilletti C, Colone A, et al. (2012) A new Mycobacterium tuberculosis smooth colony reduces growth inside human macrophages and represses PDIM Operon gene expression. Does an heterogeneous population exist in intracellular mycobacteria? Microb Pathog 53: 135-146. doi:10.1016/j.micpath.2012.06.002. PubMed: 22771837.
35. Bhatt A, Fujiwara N, Bhatt K, Gurcha SS, Kremer L, et al. (2007) Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice. Proc Natl Acad Sci U S A 104: 5157-5162. doi:10.1073/pnas.0608654104. PubMed: 17360388.
36. Fine PE, (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345. doi:10.1016/S0140-6736(95)92348-9. PubMed: 7475776.
37. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, et al. (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393: 537-544. doi:10.1038/31159. PubMed: 9634230.
38. Camacho LR, Ensergueix D, Perez E, Gicquel B, Guilhot C, (1999) Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature-tagged transposon mutagenesis. Mol Microbiol 34: 257-267. doi:10.1046/j.1365-2958.1999.01593.x. PubMed: 10564470.
39. Tufariello JM, Jacobs WR Jr., Chan J, (2004) Individual Mycobacterium tuberculosis resuscitation-promoting factor homologues are dispensable for growth in vitro and in vivo. Infect Immun 72: 515-526. doi:10.1128/IAI.72.1.515-526.2004. PubMed: 14688133.
40. Puri RV, Reddy PV, Tyagi AK, (2013) Secreted Acid Phosphatase (SapM) of Mycobacterium tuberculosis Is Indispensable for Arresting Phagosomal Maturation and Growth of the Pathogen in Guinea Pig Tissues. PLOS ONE 8: e70514. doi:10.1371/journal.pone.0070514. PubMed: 23923000.
41. Hsu T, Hingley-Wilson SM, Chen B, Chen M, Dai AZ, et al. (2003) The primary mechanism of attenuation of Bacillus Calmette-Guerin is a loss of secreted lytic function required for invasion of lung interstitial tissue. Proc Natl Acad Sci U S A 100: 12420-12425. doi:10.1073/pnas.1635213100. PubMed: 14557547.
42. Shimono N, Morici L, Casali N, Cantrell S, Sidders B, et al. (2003) Hypervirulent mutant of Mycobacterium tuberculosis resulting from disruption of the mce1 operon. Proc Natl Acad Sci U S A 100: 15918-15923. doi:10.1073/pnas.2433882100. PubMed: 14663145.
43. Copenhaver RH, Sepulveda E, Armitige LY, Actor JK, Wanger A, et al. (2004) A mutant of Mycobacterium tuberculosis H37Rv that lacks expression of antigen 85A is attenuated in mice but retains vaccinogenic potential. Infect Immun 72: 7084-7095. doi:10.1128/IAI.72.12.7084-7095.2004. PubMed: 15557632.
44. Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, et al. (2002) A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8: 1171-1174. doi:10.1038/nm765. PubMed: 12219086.
45. Baldwin SL, D'Souza C, Roberts AD, Kelly BP, Frank AA, et al. (1998) Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis. Infect Immun 66: 2951-2959. PubMed: 9596772.
46. McMurray DN, (1994) Guinea pig model of tuberculosis. In: Bloom BR, eds. Tuberculosis: pathogenesis, protection, and control. Washington, DC: American Society for Microbiology. pp.pp. 135-147.
47. McMurray DN, (2001) Disease model: pulmonary tuberculosis. Trends Mol Med 7: 135-137. doi:10.1016/S1471-4914(00)01901-8. PubMed: 11286786.
48. Chambers MA, Williams A, Hatch G, Gavier-Widén D, Hall G, et al. (2002) Vaccination of guinea pigs with DNA encoding the mycobacterial antigen MPB83 influences pulmonary pathology but not hematogenous spread following aerogenic infection with Mycobacterium bovis. Infect Immun 70: 2159-2165. doi:10.1128/IAI.70.4.2159-2165.2002. PubMed: 11895982.
49. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, et al. (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9: 533-539. doi:10.1038/nm859. PubMed: 12692540.
50. Kamath AT, Fruth U, Brennan MJ, Dobbelaer R, Hubrechts P, et al. (2005) New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development. Vaccine 23: 3753-3761. doi:10.1016/j.vaccine.2005.03.001. PubMed: 15893612.
51. Reddy PV, Puri RV, Chauhan P, Kar R, Rohilla A, et al. (2013) Disruption of Mycobactin Biosynthesis Leads to Attenuation of Mycobacterium tuberculosis for Growth and Virulence. J Infect Dis, 208: 1255-65. doi:10.1093/infdis/jit250. PubMed: 23788726.